[Diabetic nephropathy; clinical stage and prediction]

Area of Science:

• Nephrology
• Genetics
• Endocrinology

Context:

• Diabetic nephropathy (DN) is the primary cause of end-stage renal disease in Japan.
• DN progresses through five clinical stages, from pre-nephropathy to end-stage renal disease requiring renal replacement therapy.
• Current survival rates for patients on hemodialysis due to DN are unsatisfactory.

Purpose:

• To summarize the clinical stages and therapeutic options for diabetic nephropathy (DN).
• To identify predictors and risk factors associated with DN development beyond hyperglycemia.
• To explore the role of genetic polymorphisms in DN susceptibility.

Summary:

• Diabetic nephropathy (DN) presents in five stages, with interventions like glycemic control and ACE inhibitors showing efficacy in early stages (2 and 3A).
• Later stages (3B and 4) involve managing declining renal function with antihypertensive therapy and low-protein diets, while stage 5 requires renal replacement therapy.
• Factors beyond hyperglycemia, including prediabetic hypertension, parenteral hypertension, smoking, male gender, advanced age, and angiotensin-converting enzyme gene insertion/deletion polymorphism, are associated with DN.
• The development of DNA testing may enable the identification of gene polymorphisms, aiding in the detection of individuals at high risk for DN.

Impact:

• Improved understanding of DN progression and risk factors can lead to earlier detection and intervention.
• Identifying genetic predispositions may pave the way for personalized risk assessment and targeted preventive strategies for DN.
• Further research into genetic polymorphisms could enhance the prediction of DN development in type 2 diabetic patients.